FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB	APP	RO\	/AI

OMB Number:	3235-0287
Estimated average burd	en
hours nor recogness:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defen 10b5-1(c). See I	ise conditions of Rule instruction 10.			
Name and Address of Reporting Person* Bigora Sian			2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]	Relationship of Reporting Person(s) to Issuer (Check all applicable) Disease: ANY Owner (Check all applicable)
(Last) (First) (Middle)		, ,	3. Date of Earliest Transaction (Month/Day/Year) 04/05/2024	Director 10% Owner Officer (give title Other (specify below) below)
C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106				Chief Development Officer
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
HANOVER ————	MD	21076		
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	04/05/2024		M		1,675	A	(1)	21,827	D	
Common Stock	04/05/2024		F		368	D	\$2.79	21,459	D	
Common Stock	07/10/2024		M		644	Α	(1)	22,103	D	
Common Stock	07/10/2024		F		225	D	\$1.71	21,878	D	
Common Stock								6,668	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Restricted Stock Units	\$0	06/28/2024		A		3,233		(2)	(2)	Common Stock	3,233	\$0	24,728	D	
Restricted Stock Units	\$0	06/28/2024		A		2,425		(3)	(3)	Common Stock	2,425	\$0	27,153	D	
Restricted Stock Units	\$0	06/28/2024		A		404		(4)	(4)	Common Stock	404	\$0	27,557	D	
Restricted Stock Units	\$0	06/28/2024		A		404		(4)	(4)	Common Stock	404	\$0	27,961	D	

Explanation of Responses:

- 1. Distribution of vested restricted shares.
- 2. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
- 3. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
- 4. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

/s/ Sian Bigora by Michael B. Kirwan, as Attorney-in-Fact

08/02/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.